Related Experiment Video
Updated: Mar 11, 2026
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
[New Classification for Advanced Colorectal Cancer Using CancerPlex®Genomic Tests]
Hitoshi Kameyama1, Yoshifumi Shimada, Hiroshi Ichikawa
11Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences.
Abstract:
Recently, targeted drugs have been developed for the treatment of colorectal cancer(CRC). Among targets, it is well known that KRAS mutations are associated with resistance to epidermal growth factor receptor(EGFR)monoclonal antibodies. However, response rates using anti-EGFR monotherapy for CRC were less than 20-30% in previous clinical studies. Thus, because the RAS/MAP2K/MAPK and PI3K/AKT pathways are associated with CRC resistance to chemotherapy, we analyzed gene mutations in Stage IV CRC patients using a genomic test(CancerPlex®). Medical records were reviewed for 112 patients who received treatment for CRC between 2007 and 2015 in Niigata University Medical and Dental Hospital or Niigata Cancer Center Hospital. There were 66 male and 46 female patients, and their median age was 62.5(range, 30-86) years. Cluster analyses were performed in 110 non-hypermutated Japanese CRC patients using Euclidean distance and Ward's clustering method, and 6 typical groups were identified. Among these, patients with all wild-type actionable genes benefited from anti-EGFR therapies. The expense of targeted drugs warrants consideration of cost-effectiveness during treatment decision-making for advanced CRC patients. To this end, based on the genetic information on CRC, it is possible to develop precision medicine using CancerPlex®.
Insights
Genomic testing identified patient subgroups in advanced colorectal cancer (CRC). Patients with wild-type actionable genes responded well to anti-EGFR therapies, enabling precision medicine.
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- Colorectal cancer (CRC) treatment has advanced with targeted drugs.
- KRAS mutations are linked to resistance against epidermal growth factor receptor (EGFR) therapies.
- Previous anti-EGFR monotherapy response rates for CRC were below 30%.
Purpose of the Study:
- To analyze gene mutations in Stage IV CRC patients using genomic testing (CancerPlex®).
- To identify patient subgroups that may benefit from specific targeted therapies.
- To explore the potential for developing precision medicine approaches in advanced CRC.
Main Methods:
- Retrospective review of 112 Stage IV CRC patients' medical records (2007-2015).
- Genomic analysis using CancerPlex® to identify gene mutations.
- Cluster analysis of 110 non-hypermutated Japanese CRC patients to identify distinct groups.
Main Results:
- Six distinct patient groups were identified through cluster analysis.
- Patients with all wild-type actionable genes demonstrated significant benefit from anti-EGFR therapies.
- Genomic information can guide treatment decisions for advanced CRC.
Conclusions:
- Genomic profiling using CancerPlex® can stratify advanced CRC patients.
- Tailoring anti-EGFR therapy based on genetic profiles improves treatment efficacy.
- Precision medicine strategies are crucial for optimizing cost-effectiveness and outcomes in advanced CRC treatment.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
